CA
NZ
UK
AU
IND
US
REGENXBIO (NASDAQ:RGNX) climbed 10.61% to about $8.91, a notable rebound for a gene-therapy developer that has weathered a turbulent stretch. The company sits at a pivotal moment, preparing a key regulatory submission for its Duchenne muscular dystrophy program even as it manages the fallout …
● SCTX shares fell 16.23%, pulling back from the low $30s after more than doubling from its $15 IPO price in late July.
Profusa, Inc. (NASDAQ:PFSA) jumped 9.17% in a session that underscored just how volatile the micro-cap medical-technology name has become. The biosensor developer has swung violently in both directions through August, and the latest gain looks more like a bounce within a turbulent stretch than …
MapLight Therapeutics (NASDAQ:MPLT), a newly public central-nervous-system biotech, climbed roughly 10% as investors continued to reassess a name that has whipsawed since its market debut. The stock has become a focal point for traders drawn to the volatile intersection of neuroscience and clinical-trial catalysts.
Pulmonx (NASDAQ:LUNG), the medical-device maker behind the Zephyr Endobronchial Valve for severe emphysema, rose 9.65% as investors reassessed a stock that has been deeply out of favor for much of the past two years.
Kura Oncology (NASDAQ:KURA) jumped 9.60% as investors responded to fresh clinical data for its menin inhibitorFranchiseand the early commercial ramp of its first approved medicine, marking a notable step in the company's transition from clinical-stage developer to commercial oncology player.
Lexaria Bioscience (NASDAQ:LEXX), a drug-delivery company whose DehydraTECH platform aims to improve oral GLP-1 medications, rose 10.06% as traders returned to a volatile micro-cap tied to one of the hottest themes in healthcare. The move came in the wake of a recentReverse Stock Splitthat …
Emergent BioSolutions Inc. (NYSE:EBS) gained 8.88% in a rebound that came weeks after a second-quarter report which had pressured the stock. The specialty-biopharmaceutical company, known for medical countermeasures and its naloxone franchise, has been working through a difficult stretch marked by naloxone-market pressure and …
Editas Medicine (NASDAQ:EDIT) advanced 9.33% as gene-editing sentiment strengthened and investors reassessed a company that has repositioned itself around in vivo editing after stepping back from an earlier ex vivo focus.
● ELAB shares fell 12.73% following the company's mid-August announcement of an anticipated reverse stock split.
Please wait processing your request...